Why Is AI Validation Different From Traditional CSV?

If you have done Computer System Validation (CSV) for an electronic batch record system or a LIMS, you know the framework: write user requirements, functional specifications and detailed design specifications, run IQ/OQ/PQ protocols, document results, lock the system, manage changes through formal change control. The system is deterministic that provides the same output to the same input every time. That predictability is exactly what traditional validation is built on.

AI systems break that assumption. An AI model produces probabilistic outputs. Its behavior can shift as it processes new data. If you are using a machine learning model to flag deviations, analyze batch data, or support release decisions, the question “does this system do what we validated it to do?” becomes genuinely difficult to answer with static documentation.

The practical consequence: AI in GMP environments requires a shift from static validation (validate once, manage exceptions) to continuous validation (ongoing monitoring of model performance, drift detection, and defined re-validation triggers). The data feeding the model matters as much as the model itself.

Key term: Model drift — when an AI model’s outputs shift over time as the data it processes changes, even though no one intentionally updated the model. In a GMP context, drift without detection is a data integrity risk.

What Regulations Apply to AI in GMP Manufacturing?

Existing regulations apply fully. There is no AI carve-out in FDA’s current framework. If your AI tool generates, modifies, or archives electronic records in a GMP context, 21 CFR Part 11 requirements apply: audit trails, electronic signatures, access controls, and data integrity controls. 21 CFR Part 211 and Part 820 also apply to any automated system involved in production or quality decisions.

FDA Draft Guidance — January 2025

The FDA published “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products” (January 7, 2025). This guidance introduces a risk-based credibility assessment framework for AI models. The core principle: your validation effort should be proportional to how consequential the model’s output is.

FDA–EMA Joint Guiding Principles — January 2026

The FDA and EMA jointly issued Guiding Principles of Good AI Practice in Drug Development (January 14, 2026) which has ten principles spanning research through manufacturing and safety monitoring. This document suggests that there will be converging expectations between US and European regulators.

ISPE GAMP Guide: Artificial Intelligence — July 2025

ISPE released the GAMP Guide: Artificial Intelligence in July 2025, the first comprehensive industry framework dedicated entirely to validating AI-enabled systems in GxP environments. It provides practical guidance on risk classification, continuous validation, data governance, and the human oversight requirements that surround AI decision-making in regulated manufacturing.

EU GMP Annex 22 — Draft 2025, Final Expected 2026

The European Commission opened consultation in 2025 on a new Annex 22 on Artificial Intelligence, drafted by the EMA GMDP Inspectors’ Working Group with PIC/S. If you manufacture or sell into European markets, this is not a future planning item. It is a current compliance consideration.

“The FDA and EMA have made clear: existing rules apply, new frameworks are forming, and manufacturers who wait for final guidance before acting will be behind.”

What Is the FDA’s Risk-Based Credibility Framework?

The January 2025 FDA draft guidance introduces credibility assessment as the organizing principle for AI validation. The rigor of your validation documentation should match the risk profile of what the AI is doing.

A low-risk use case like an AI tool that summarizes training completion records for a manager’s review requires lighter documentation than a high-risk one, such as an AI model that analyzes in-process data to recommend batch disposition. The framework asks: How consequential is the output? What happens if the model is wrong? How much human review stands between the model’s output and a regulated decision?

This risk-based approach also underpins the Predetermined Change Control Plan (PCCP) concept, which allows manufacturers to pre-define acceptable categories of model updates and get them approved in advance, rather than filing a formal change control supplement every time the model is retrained or adjusted. Think of it as a validated change corridor: you define the boundaries upfront, and changes within those boundaries do not require individual review.

What Does Good AI Validation Look Like in Practice?

The ISPE GAMP Guide: Artificial Intelligence (2025) offers the clearest practical framework. Its key contributions:

Continuous validation over static validation. AI models require ongoing performance monitoring rather than a single validation event. Define your acceptable performance thresholds, monitor for drift, and document what triggers a re-validation.

Validate the data, not just the algorithm. An AI system is only as reliable as the data it was trained on and continues to receive. Inconsistent batch records, manual inventory inputs, and unstandardized SOPs create data quality problems that no amount of model tuning will fix.

Validate the sociotechnical system. The GAMP guide is explicit: validate the whole system — the data infrastructure, the processes surrounding the AI, and the human oversight mechanisms. Who reviews the model’s outputs? What decisions can the model influence autonomously?

Document the intended use precisely. The narrower and more specific your documentation of what the AI is and is not authorized to do, the stronger your validation posture. Vague intended-use statements invite inspection findings.

Practical test: if an FDA investigator walked in tomorrow and asked to see the validation documentation for your AI tool, could you hand it to them? If the answer is “not yet” or “the vendor handles that” — you have work to do.

How Does InstantGMP Support AI Validation?

InstantGMP is pre-validated software developed per GAMP 5 guidelines and the FDA General Principles of Software Validation. The Installation Qualification and Operational Qualification are performed on the cloud-based platform, so customers begin with a validated foundation rather than building one from scratch.

For AI deployment specifically, that foundation is what makes compliance achievable. The requirements that AI validation places on your data environment such as traceable records, controlled documents, complete audit trails, standardized workflows are exactly what InstantGMP is built to provide:

Electronic Batch Records: Structured, traceable production records that meet 21 CFR Part 11 audit trail requirements. Clean, consistent batch data is the input AI systems depend on.

Document Management: Version-controlled SOPs, work instructions, and quality documents are the standardized documentation layer that makes AI-assisted SOP writing and review reliable.

Quality Management System: Deviation management, CAPA, change control makes up the process infrastructure that captures how model changes are reviewed and approved.

AI Insights: InstantGMP’s built-in AI Insights features are developed within the same validated, Part 11-compliant environment as the rest of the platform. AI-generated outputs are traceable, auditable, and governed by the same access controls as all other system records.

“We are adapting AI as a tool to improve our electronic software solutions and to improve our quality management systems — and we learned that it only works when the underlying documentation is already traceable and controlled.” — Richard Soltero, Ph.D., Founder, InstantGM

How InstantGMP Validates Its AI Features

InstantGMP’s AI features are built on a Model Context Protocol (MCP) server that connects the platform to large language models. Validation of this architecture follows a layered protocol that addresses both traditional computer system validation requirements and the AI-specific challenges described above.

Step 1 — Operational Qualification of the MCP Server APIs

Every API called by the InstantGMP MCP server is validated as part of the standard Operational Qualification (OQ) process. Test scripts confirm that each API returns the correct data for defined inputs, handles error conditions appropriately, and performs within acceptable response times. This step validates the data pipeline before the language model layer is introduced.

Step 2 — Reference Standard Comparison

The core AI validation methodology uses a reference standard comparison. Data is downloaded directly from the InstantGMP application  (bypassing the APIs and MCP server entirely) across each module: electronic batch records, inventory, quality management, documents, and roon and equipment logs. This direct download serves as the verified reference standard.

The same queries are then executed through the MCP server connected to the language model. The AI-generated output is compared to the reference standard against two pre-defined acceptance criteria:

Factual accuracy: every data value, record count, lot number, date, and status in the AI output must exactly match the reference standard. Zero tolerance for data discrepancy.

Presentation variation: wording, ordering, and formatting of the AI-generated report are permitted to vary between runs. The language model may describe the same data differently; this is expected and acceptable, provided the underlying facts are correct.

Acceptance criteria must be documented before testing begins. Post-hoc criteria are not acceptable under 21 CFR Part 11 data integrity requirements.

Step 3 — Reproducibility Testing

Because large language models are non-deterministic, each test query is executed a minimum of three times across separate sessions. Reproducibility is confirmed when the factual content of the AI output is consistent across all runs, even if presentation varies. Any run that produces a factual discrepancy from the reference standard is a test failure and triggers investigation before the validation is accepted.

Step 4 — Negative Testing and Hallucination Detection

A dedicated set of test cases queries the system for data that does not exist: batch records for products never manufactured, lot numbers never received, CAPAs never initiated. The expected result in every case is a clear no-results response. Any output that fabricates plausible-sounding data constitutes a test failure. This test category has no equivalent in traditional CSV; it is specific to language model behavior and is required for any AI system operating in a GMP context.

Change Control Triggers for AI Components

The following changes require a re-validation run for affected modules before deployment to production:

Language model version change: a new model release replacing the validated version.

MCP server update: changes to tool definitions, system prompts, or query logic.

Application updates: InstantGMP changes that materially affect data returned by validated APIs.

This pre-defined change control scope is the AI equivalent of a Predetermined Change Control Plan (PCCP) — boundaries established in advance so that routine model improvements do not require full re-validation unless they fall outside the approved change envelope.

Validation Documentation

Each validation cycle produces a Validation Summary Report that includes: the validated LLM model version and MCP server version; test case coverage by module; acceptance criteria and pass/fail results for each test case; reproducibility run results; negative test results; access control test results; any deviations and their disposition; and QA sign-off. This documentation is maintained as part of the InstantGMP Computer Validation package and is available to customers upon request.

“Validated AI” in a GMP context means a documented protocol, defined acceptance criteria, reproducibility evidence, and a change control plan; it’s not a vendor statement. InstantGMP’s validation package is built to that standard.